ONTELRIQ Trademark

Trademark Overview


On Wednesday, February 16, 2022, a trademark application was filed for ONTELRIQ with the United States Patent and Trademark Office. The USPTO has given the ONTELRIQ trademark a serial number of 79337831. The federal status of this trademark filing is IR CANCELLED - US APPLICATION ABANDONED as of Saturday, April 29, 2023. This trademark is owned by IPSEN PHARMA S.A.S. The ONTELRIQ trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for use in the prevention and the treatment of cancer, orphan diseases, immune disorders, liver diseases, biliary diseases, metabolic diseases, inflammatory diseases, urological diseases, disorders and diseases of the reproductive system, puberty diseases or disorders, gynecological disorders, fertility, acromegalia and tumors, hormonal disorders, endocrine disorders, connective tissue disease, blood diseases, gastrointestinal diseases and disorders, hemophilia, gastrointestinal bleeding disorders, neurological diseases, muscle disorders, bone disorders, skeletal disorders, neuromuscular disorders, cervical dystonia, cerebral palsy, spasticity, blepharospam, migraine, bladder pain syndrome, pain, glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin; Pharmaceutical preparations containing notably botulinum toxin, botulinum toxin-haemagglutin complex, botulinum toxin fragments and other botulinum toxin derivatives for skin...
ontelriq

General Information


Serial Number79337831
Word MarkONTELRIQ
Filing DateWednesday, February 16, 2022
Status402 - IR CANCELLED - US APPLICATION ABANDONED
Status DateSaturday, April 29, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 26, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations for use in the prevention and the treatment of cancer, orphan diseases, immune disorders, liver diseases, biliary diseases, metabolic diseases, inflammatory diseases, urological diseases, disorders and diseases of the reproductive system, puberty diseases or disorders, gynecological disorders, fertility, acromegalia and tumors, hormonal disorders, endocrine disorders, connective tissue disease, blood diseases, gastrointestinal diseases and disorders, hemophilia, gastrointestinal bleeding disorders, neurological diseases, muscle disorders, bone disorders, skeletal disorders, neuromuscular disorders, cervical dystonia, cerebral palsy, spasticity, blepharospam, migraine, bladder pain syndrome, pain, glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin; Pharmaceutical preparations containing notably botulinum toxin, botulinum toxin-haemagglutin complex, botulinum toxin fragments and other botulinum toxin derivatives for skin care and the treatment of neurological disorders; pharmaceutical preparations containing botulinum toxin with specified components of the toxin haemagglutin complex for skin care and the treatment of neurological disorders

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes052, 051, 005, 018, 006, 044, 046
Class Status CodeH - NOT AVAILABLE
Class Status DateSaturday, April 29, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameIPSEN PHARMA S.A.S
Party Type20 - Owner at Publication
Legal Entity Type34 - NOT AVAILABLE
AddressFR

Party NameIPSEN PHARMA S.A.S
Party Type10 - Original Applicant
Legal Entity Type34 - NOT AVAILABLE
AddressFR

Trademark Events


Event DateEvent Description
Tuesday, November 21, 2023NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Monday, November 20, 2023DEATH OF INTERNATIONAL REGISTRATION
Tuesday, October 31, 2023NOTIFICATION PROCESSED BY IB
Tuesday, October 3, 2023NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Tuesday, September 26, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 26, 2023PUBLISHED FOR OPPOSITION
Wednesday, September 13, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, September 13, 2023NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Wednesday, September 6, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, September 6, 2023NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, September 6, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 22, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 19, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, July 19, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, July 19, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, February 27, 2023REFUSAL PROCESSED BY IB
Friday, January 27, 2023NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, January 27, 2023REFUSAL PROCESSED BY MPU
Saturday, December 10, 2022NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, December 9, 2022NON-FINAL ACTION WRITTEN
Thursday, December 1, 2022ASSIGNED TO EXAMINER
Tuesday, April 12, 2022APPLICATION FILING RECEIPT MAILED
Friday, April 8, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, April 7, 2022SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB